Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently causing a worldwide pandemic. Development of animal models that recapitulate coronavirus disease 2019 (COVID-19) are essential for evaluating vaccines and antivirals, and for understanding the pathogenesis of the disease. Although several SARS-CoV-2 animal models have been described to date, such as monkeys, ferrets, and hamsters 1–6, mice are considered to be better suited for use as animal models given their small size, rapid breeding cycles, and well-characterized immunological background. However, due to the lack of the viral entry receptor, human angiotensin converting enzyme (hACE2), laboratory mouse strains are non-permissive to the circulating SARS-CoV-2 infection7–9. Several groups have reported mice that either permanently or transiently express hACE2. There are three transgenic mouse models using different promoters to drive permanent hACE2 expression, including a universal cytomegalovirus (CMV) enhancer/beta-actin promoter10, epithelial cell-specific promoter (K-18 or HFH4)11,12 and the endogenous mouse ACE2 promoter13. Nevertheless, the production of hACE2 transgenic mice is time-consuming and their versatility is limited as they are restricted to a single genetic background. hACE2 expression in mice can be achieved rather quickly by adeno-associated virus (AAV)- or adenovirus type 5 (Ad5)-mediated transduction. SARS-CoV-2 replication in mice sensitized by AAV-hACE2 transduction appears to be lower than that reported in other mouse models14. Transduction of mice with CMV promoter-driven hACE2-expressing Ad5 confers SARS-CoV-2 susceptibility, but only mild to moderate pulmonary pathogenesis has been induced by SARS-CoV-2 infection15,16. The induction of an antiviral immune response to the adenovirus vector itself is supposed to have a negative effect on SARS-CoV-2 infection, which may inhibit severe disease in the mouse respiratory tract.
The commonly used CMV-driven transgene-expressing Ad5 vectors lack the intrinsic viral E1 gene that is essential for adenovirus growth, where a transgene can be inserted. When the expression unit was inserted in the rightward orientation, a viral pIX gene located downstream of the inserted unit was co-expressed with the transgene, and a fusion protein consisting of the N-terminal part of transgene product was expressed. These pIX products may be one of the main causes of adenovirus-induced immune responses. Interestingly, the EF1α promoter did not activate the pIX promoter in this adenoviral vector17. The EF1α promoter with a leftward orientation resulted in a reduced antiviral response and maintained prolonged transgene expression17. Thus, we generated an adenoviral vector expressing hACE2 under the EF1α promoter with a leftward orientation (rAd5 pEF1α-hACE2-L) (Fig. 1a). We first examined whether intranasal administration of rAd5 pEF1α-hACE2-L affects the body weight of BALB/c mice, and found that administration at 5×107 or 2.5×108 focus forming units (FFU) per mouse did not cause any decrease in body weight (Fig. 1b). Next, BALB/c mice were intranasally administered with rAd5 pEF1α-hACE2-L at 1⋅107, 5⋅107 or 2.5⋅108 FFU/animal. Five days after administration, mice were further intranasally inoculated with an early circulating strain of SARS-CoV-2 isolated in Japan (originated from Wuhan; Wu-2020 strain) at 1⋅105 plaque forming units (PFU) per mouse (Fig. 1c). As a result, the 5⋅105 FFU rAd5/mouse group showed a marked reduction in body weight, which peaked at 5-6 days post-infection (dpi) with SARS-CoV-2 Wu-2020. Although the 2.5⋅108 FFU rAd5/mouse group showed weight loss until 4 dpi of SARS-CoV-2 infection, this group showed recovery of body weight after 5 dpi. The 1⋅107 FFU rAd5/mouse group showed a slight reduction of weight followed by rapid recovery. Therefore, we determined that 5⋅107 FFU rAd5/animal was the most suitable dose for assessing disease severity. Comparison of low (1⋅104 PFU/mouse) and high (1⋅105 PFU/mouse) titers of SARS-CoV-2 infection demonstrated that weight loss was more apparent in the high-titer group, approximately 25% maximum (Fig. 1d). Dark red and brown lesions were observed on the surfaces of lungs infected with 1×105 PFU of SARS-CoV-2 at 7 dpi (Fig. 1e). Histopathologically, SARS-CoV-2 infected lungs showed evidence of severe pneumonia with profound infiltration of leukocytes, including macrophages, neutrophils and lymphocytes, in alveoli with thickened epithelium, hemorrhaging and improved blood coagulation (Fig. 1e).
Variants of concern (VOCs) have emerged showing evidence of altered virus characteristics18. VOCs have been associated with increased transmissibility, evasion of immunity from infection and vaccination, and reduced susceptibility to antibody therapies19–21. Large population studies have observed a significant trend toward increased mortality associated with B.1.1.722,23. We studied the pathogenesis of VOCs [QHN001 (B.1.1.7), TY7-501 (P.1) and TY8-612 (B.1.351)], which were clinically isolated in Tokyo. We first examined the growth characteristics of these VOCs and the Wu-2020 strain in Vero E6/TMPRSS2 cells24 at a multiplicity of infection (MOI) of 0.001, and found that the growth kinetics were almost comparable among strains (Fig. 2a). To analyze their replication in mouse lungs, we inoculated the rAd5 pEF1α-hACE2-L administered BALB/c mice with SARS-CoV-2 via the intranasal route. Viral replication in the lungs was examined by quantitative real-time RT-PCR (qRT-PCR) for the detection of SARS-CoV-2 genome, and by plaque assay using Vero E6/TMPRSS2 cells. A clear increase in viral replication was observed with a peak at 2 dpi in all strains (Fig. 2b and 2c), followed by a gradual decrease towards 7 dpi. The B.1.351 strain showed reduced genome copy numbers (significantly at 7 dpi), but other strains showed comparable genome copy numbers throughout the course of infection. Macroscopically, in Wu-2020- and B.1.1.7 strain-infected lungs, multiple dark red and brown lesions appeared on the surfaces of all lung lobes from 4 to 7 dpi (Fig. 2d, arrows). In contrast, the discolored lesions were restricted to the upper left lobe in P.1- and B.1.1351 strain-infected lungs at 7 dpi. The loss of body weight in mice did not correspond to the extent of viral replication and lung lesions (Fig. 2e). The B.1.351 strain, an exception, showed less viral replication and lesions in the lungs, so the degree of weight loss was lower throughout the course of infection. Although viral replication was similar in the B.1.1.7 and P.1 strains, the appearance of lung lesions was more pronounced in B.1.1.7, however, weight loss was relatively more pronounced in P.1. Mice infected with all four strains continued to lose weight until 5 dpi, but mice infected with three VOCs began to recover thereafter. Though viral replication and the extent of lung lesions were comparable in B.1.1.7- and Wu-2020-infected mice, mice infected with Wu-2020 did not regain weight, resulting in significant weight loss at 7 dpi compared with mice infected with VOCs (Fig. 2e).
The histopathological analysis demonstrated that severe pneumonia with thickened alveolar walls, inflammatory cell infiltration, hemorrhaging, and thrombus formation was remarkable in the dark red and brown lesions of the lung (Fig. 3a, hematoxylin and eosin staining; HE). Even in areas where discoloration was not obvious macroscopically, thickened alveolar walls and mild infiltration of inflammatory cells were observed (Supplementary Fig. 1, HE). Immunohistochemistry using an antibody against SARS-CoV-2 nucleocapsid (N) protein showed that the viral antigen was present in the lung epithelial cells (Fig. 3a and supplementary Fig. 1). The viral antigen was stained most prominently at 2 dpi. Few viral antigens were found in lesions with remarkable cellular infiltration.
Next, we examined cytokine expression in the lung using a multiplex bead array. Inflammatory cytokine, such as IL-6, was significantly elevated in all strains compared to mock-infected animals (Fig. 3b). Furthermore, IL-1b, IFN-g, IL-12, MIP-1b, MIP-2, LIF, KC, IL-10, MCP-1, M-CSF, G-CSF, and GM-CSF were significantly elevated and VEGF was decreased, at least in a strain compared to mock-infected mice. In B.1.351-infected lungs, the expression of some cytokines, such as MIP2, LIF, and MCP-1, was relatively low compared to other strains. This is correlated with the manifestation of low viral replication and mild weight loss. For infection by other strains, there was no clear evidence of a relationship between cytokine levels and disease severity.
The clinical severity of COVID-19 is not always associated with increased levels of pro-inflammatory cytokines and other inflammation markers25. To survey the molecules associated with disease severity, tandem mass tag (TMT) peptide labeling, combined with mass spectrometry (MS) quantitative proteomics in mouse lung at 7 dpi with SARS-CoV-2 was performed. The TMT-based quantitative proteomic method was approved previously for comparison of protein levels across multiple organs in human COVID-19 autopsy cases26. TMTpro 12-plex MS revealed distinct lung proteomes associated with infection by SARS-CoV-2 strains (Fig. 4a and Supplementary Fig. 2a). Gene ontology (GO) enrichment analysis of significantly (p<0.05) up- and down-regulated (2-fold) proteins showed that the proteome of Wu-2020-infected lung was distinct from those of other variants (Fig. 4b). Immune response-related factors, such as regulation of complement activation, immune effector process, as well as platelet degranulation and regulation of blood coagulation, were enriched in the proteins that changed significantly in the proteome of Wu-2020-infected lungs (Fig. 4b). In contrast, the proteomes of VOC-infected lungs were associated with structural organization, such as the development of extracellular structures and changes in matrix organization, as well as nuclear DNA replication. Up-regulation of proteins associated with complement activation, e.g., C3a anaphylatoxin chemotactic receptor, complement components and complement factors was prominent in Wu-2020-infected lungs (Fig. 4c). The complement system has been shown to be involved in the severity of human COVID-1927,28. Up-regulation of proteins involved in platelet degranulation and blood coagulation, e.g., kininogen, fibronectin, plasminogen activator inhibitor-1, coagulation factor XII and plasma kallikrein, was also remarkable in Wu-2020-infected lung tissue (Fig. 4d and f). These factors are considered to work in concert and contribute to COVID-19 pneumonia via dysregulation of thrombus formation. Up-regulation of minichromosome maintenance complex component (MCM)2, 3, 4, 5, 6, and 7, which are related to nuclear DNA replication, was observed in SARS-CoV-2 infection, regardless of strain (Fig. 4g). MCM2-7 act as replicative DNA helicases that unwind the DNA duplex template as a hetero-hexameric complex29. The involvement of the MCM family in immune responses against viral infection is still poorly characterized. However, MCM up-regulation is correlated with proliferation and maintenance of leukocytes30,31, suggesting that the MCM family is involved in the activation of infiltrating cells in the COVID-19 pneumonia observed in lungs infected with all of the virus strains. Structural organization-related proteins, such as collagens, were down-regulated in VOC-infected lungs (Fig. 4e). Collagen deposition is a hallmark of lung fibrosis32 and has been confirmed in the lungs of COVID-19 patients33. It is considered that collagen deposition may be correlated with mild disease onset based on the recovery of body weight in VOC-infected mice. Pathway analysis based on Wikipathways (https://www.wikipathways.org/index.php/WikiPathways) supports the enrichment of complement and coagulation cascades, as well as the blood-clotting cascade, in Wu-2020-infected lungs (Supplementary Fig. 4).
We established a system to recapitulate COVID-19-like pneumonia in mice infected with SARS-CoV-2 after inducing hACE2 with rAd5 pEF1α-hACE2-L. When rAd5 pEF1α-hACE2-L was used, there were few abnormalities in protein expression (Supplementary Fig. 2a), suggesting that this adenoviral vector has low cytotoxicity. Mice infected with the Wu-2020 strain developed diffuse pneumonia. Histopathologically, thickened alveolar walls, hemorrhaging, and infiltration of inflammatory cells were prominent. The SARS-CoV-2 N antigen was found in alveolar epithelial cells, not in the lesions infiltrated by inflammatory cells; rather, the antigen was concentrated in areas that retained relatively normal alveolar structure. These findings were consistent with human COVID-19 autopsy cases in early 202034,35.
SARS-CoV-2 Wu-2020, an early circulating strain, was shown to be highly pathogenic in mouse lung. The Wu-2020, B.1.1.7 and P.1 strains have comparable replication potentials in both Vero E6/TMPRSS2 cells and mouse lung (Fig. 2a-c). In addition, these strains induced a marked cytokine response (Fig. 3b), and infection led to similar histopathological findings (Fig. 3a and Supplementary Fig. 1). However, there was a clear difference in the lung proteome (Fig. 4b) between the Wu-2020 strain, which induced prolonged weight loss, and the other strains, which induced weight loss followed by recovery (Fig. 2e). The findings showed that proteins involved in the complement system were elevated most markedly in cases of Wu-2020 infection (Fig. 4b and c). The release of proinflammatory complement peptides helps to recruit leukocytes to the lung and aids in the assembly of the terminal complex that damages vascular endothelium27,28,36. Increased levels of complement fragments is related to disease severity in COVID-19 patients27,37, which suggests that they are well suited for use as a marker for serious injury in Wu-2020-infected lung. The altered blood coagulation system, which is manifested by the up-regulation of thrombosis-associated proteins, such as tissue factor (TF), coagulation factor XII and plasma kallikrein (Fig. 4f), can also be involved in disease severity in Wu-2020-infected lungs. TF initiates the extrinsic coagulation pathway to form thrombin in response to tissue injury and inflammation38–41. Coagulation factor XII is activated by polyphosphates released from platelets, and initiates an intrinsic coagulation cascade.42–44, which occurs with disease onset in acute respiratory distress syndrome45. Factor XII also activates plasma kallikrein, thereby increasing the formation of the proinflammatory peptide bradykinin46. Simultaneously, several inhibitory factors for complement activation, such as complement factor H and vitronectin (Fig. 4c), and for coagulation, such as plasminogen which activates fibrinolysis (Fig. 4d), were up-regulated in Wu-2020-infected lungs; these factors may play a role for prevention of excessive tissue injury. These results indicate that molecular events in pneumonia lesions are altered in ways that cannot be observed by morphological observation. Even in these cases, the lung damage associated with elevated proteins that are related with complement activation, platelet degranulation and blood coagulation may result in the manifestation of severe symptoms, such as unrecovered weight loss after Wu-2020 infection.
In this study, levels of pro-inflammatory cytokines could not be used as markers of disease severity. Rather, the findings showed that complement-related and blood coagulation factors may be key factors associated with COVID-19 severity. In addition, we observed 35-fold and 9-fold up-regulation of metallothionein-2 (Mt2) and Mt1, respectively, in Wu-2020-infected lung (Supplementary Fig. 3). Mt1/2, which are potently induced by heavy metals, other sources of oxidative stress and cytokines, facilitate metal binding and detoxification47. In response to GM-CSF, macrophages express Mts (Mt2 rather than Mt1), which are involved in antimicrobial responses and contribute to the production of reactive oxidative species48. We observed a correlation between disease severity and Mt1/2 amount, suggesting that Mt1/2 may act as a marker for COVID-19 severity. Additionally, we identified other potential biomarkers that may be correlated with disease severity, including tenascin, membrane-spanning 4-domains subfamily A member 6C and stefin-1/3 (Supplementary Fig. 3), whose associations with COVID-19 have not been studied to date. Furthermore, abundance of the SARS-CoV-2 N protein in lungs infected with Wu-2020 was markedly higher than that in other strains (Supplementary Fig. 3). SARS-CoV-2 N protein has been shown to promote NLRP3 inflammasome activation49, and it is possible that SARS-CoV-2 N protein remaining in the lung may stimulate excessive inflammation. The amount of residual SARS-CoV-2 N protein in lesions may also be indicative of lung injury. It is possible that a comparison of SARS-CoV-2 strains that exhibit different pathogenicity may reveal the existence of novel biomarkers for disease severity.
Intrinsic etiological differences in VOCs have not been demonstrated. Although the B.1.1.7, P.1, and B.1.351 strains do not show increased pathogenicity in hamsters50–53 or rhesus macaques54, B.1.1.7 and B.1.351 strains showed high pathogenicity in the K-18 hACE2 Tg mouse model55,56. Our findings revealed that there is a difference in the manifestation of symptoms associated with SARS-CoV-2 strains, and that an early isolated strain was highly pathogenic in the lung. The major difference between our findings and previous studies is that the respiratory-specific pathogenesis of SARS-CoV-2 was recapitulated in the mouse model using rAd5 pEF1α-hACE2-L in this study. SARS-CoV-2 infection involves extra-respiratory manifestations, including cardiac, gastrointestinal, hepatic, renal, and neurological symptoms. Disease severity in K-18 mice infected with B.1.1.7 and B.1.351 strains may be due to these extra-respiratory symptoms, as shown by the presence of neurological pathogenesis57,58. Comparative studies of human autopsy cases of each variant have not yet been performed. Some autopsy cases of patients infected with the B.1.1.7 and P.1 strains revealed no significant morphological or histopathological differences compared to early circulating strains59,60. However, our findings showed that the elevation of several potent biomarkers may affect lung pathogenesis. Understanding the overall differences in an organ’s proteome can help to unravel the pathology of emerging variants. With the accumulation of autopsy cases infected with VOCs, these changes in pathologies will be revealed.
In conclusion, we demonstrated that an early circulating SARS-CoV-2 specifically induces the manifestation of severe symptoms and is associated with dramatically altered host responses. How pathogenicity was transformed from the initial strains to that observed in the VOCs needs to be elucidated. Detailed analyses of the pathogenicity of the early circulating strains will lead to a better understanding of the origin of the pandemic.